Dr Gelareh Zadeh
Targeting clinically challenging meningiomas
Almost a quarter of all primary brain tumours in adults are meningiomas. As many as 90% are low grade meningiomas (Grades 1 and 2) but there is a small subset that are more aggressive (Grade 3).
Meningiomas develop in the membrane that cover and protect the brain and spinal cord. Current treatments depend on the size, location and nature of the tumour, but there are no targeted treatments, yet.
Here are the research projects we are currently funding that relate to understanding or treating meningioma.
Dr Zadeh and the team are investigating what make clinically aggressive meningiomas (CAMs) and radiation induced meningiomas (RIMs) different, and hard to treat.
Here are the research projects we are currently funding that relate to understanding or treatment of childhood brain tumours including meningiomas.
Previous research has demonstrated that chromatin regulation is often disrupted in many cancers. Mutations, or changes, in histone proteins leads to the initiation of many cancers, including gliomas.
The aim of the research, led by Dr Wong, is to understand the role of a specific histone protein, called H3.3, and how changes in this protein drive tumour growth.
Survival rates for individuals diagnosed with gliomas depend on a host of factors, but only 19% of adults diagnosed with a brain tumour survive for five years after their diagnosis. So it’s important that further research is done to inform our understanding of how and why these tumours start.